Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

'Pivotal Topline Up Next' for Biotech's Phase 3 Cardiac Clinical Trial

A study update and the next steps to advance the therapeutic were covered in a ROTH Capital Partners report. In an April 25 research note, ROTH Capital Partners analyst Jotin Marango reported that the last required major adverse cardiac event, the 250th, occ...
Streetwise Reports | May 2, 2019 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

Revolutionizing vascular grafting with a durable solution

Our next guest is a multi-technology biomedical company, focused on the development and commercialization of medical technologies. Marizyme Inc. (OTCQB:MRZM) has had its sights set on development of medical technology and products, one of which is DuraGraft. J...
Brieanna McCutcheon | September 27, 2023 |

Hemostemix Founder: A Man with a Compassionate Heart

The Canadian stem cell company Hemostemix Inc. ( TSX-V: HEM , OTC: HMTXF ) was founded by a man who truly had a compassionate heart and a clear intent to establish a breakthrough in heart disease using the same technology that saved his life. Roger Bergersen, who train...
Featured Submission | December 14, 2020 |

Medtronic Stock Hits All-Time High After Raising 2020 EPS Outlook

Dublin-based Medtronic reported Q1/20 earnings and revised its full-year earnings outlook upward sending shares up more than 5% today. Medical device developer and manufacturer Medtronic Inc. (MDT:NYSE) today announced financial results for its first quarter of fi...
Streetwise Reports | August 22, 2019 |

Zynex Shares Trade Higher After Reporting a 95% Increase in Q3 Orders

Non-invasive medical device maker Zynex Inc's. shares are trading 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018. This morning medical technology company specializing in manufacturing and s...
Streetwise Reports | October 3, 2019 |

CytoSorbents Shares Trade 20% Higher as FDA Grants CytoSorb EUA for COVID-19

Shares of CytoSorbents traded higher setting a new 52-week intraday high price after the company reported that the FDA granted emergency use authorization for CytoSorb for use in patients with COVID-19. Critical care immunotherapy company CytoSorbents Corp....
Streetwise Reports | April 14, 2020 |

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'

The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. Beaker In a May 20 research report, ROTH Capital Partners analyst Yasmeen Rahimi reported that The Medicines Company's (MDCO:...
Streetwise Reports | May 30, 2019 |

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report

Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. Structural heart disease and critical care monitor...
Streetwise Reports | July 25, 2019 |

Boston Scientific Reports 13% Q3 Sales Growth and Raises Yearly Estimates

This morning shares of Boston Scientific traded 6% higher after the firm reported a 13.1% increase in revenue for Q3/19. The firm also raised its revenue guidance for both Q4/19 and FY/19. Early this morning medical device maker Boston Scientific Corp. (BSX:NYSE) an...
Streetwise Reports | October 24, 2019 |
1 2